PF-Atlas › Clinical Trials › NCT01355796

Inhaled Xylitol Versus Saline in Stable Subjects With Cystic Fibrosis

Xylitol · Phase 1

Registry ID

NCT01355796

Phase

Phase 1

Status

Completed

Drug / intervention

Xylitol

Sponsor

Joseph Zabner

Start

2011-05

Enrollment

Locations

About this trial

Cystic fibrosis (CF) lung disease is characterized by chronic bacterial colonization and recurrent infection of the airways. Lowering the airway surface liquid (ASL) salt concentration has been shown to increase activity of salt sensitive antimicrobial peptides. Xylitol is a 5-carbon sugar that can lower the ASL salt concentration, thus enhancing innate immunity.In this study, the investigators plan to study the safety and efficacy of 2 weeks of inhaled xylitol compared to 2 weeks of hypertonic saline in a randomized crossover design in stable subjects with cystic fibrosis

View NCT01355796 on ClinicalTrials.gov →

Explore related

All Xylitol trials All IPF trials

Related trials

Xylitol — NCT00928135

Medical disclaimer. This page summarizes public trial data for NCT01355796 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.